Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database

References

• Multiple Myeloma Research Foundation. What is multiple myeloma? Philadelphia, PA. 1997. www.themmrf.org/multiple-myeloma/what-is-multiple-myeloma/
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma. Bethesda, MD. 2016. https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997;80(8 Suppl):1557-63
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Abonour R, Terebelo H, et al. Connect MM Registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk 2015;15:368-76
   PubMed Web of Science ®Google Scholar
• Talamo G, Farooq U, Zangari M, et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:464-8
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005;19:125-42
   PubMed Web of Science ®Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016;175:252-64
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer 2000;88(12 Suppl):3022-32
   PubMedGoogle Scholar
• Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res 2008;27:11
   PubMed Web of Science ®Google Scholar
• Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24:1043-9
   PubMed Web of Science ®Google Scholar
• Wisloff F, Gulbrandsen N, Hjorth M, et al. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol 2005;75:293-8
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: multiple myeloma, Version 3. NCCN; 2016. Fort Washington, PA. 2016. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
   Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2017;28:iv52-iv61
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 2015;100:1254-66
   PubMed Web of Science ®Google Scholar
• Nash Smyth E, Conti I, Wooldridge JE, et al. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. J Med Econ 2016;19:477-86
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7
   PubMedGoogle Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Statistics. UBoL. Consumer Price Index. Washington, DC. 2017. https://www.bls.gov/cpi/
   Google Scholar
• Ghali WA, Hall RE, Rosen AK, et al. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1996;49:273-8
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Groot MT, Huijgens PC, Wijermans PJ, et al. Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoecon Outcomes Res 2004;4:565-72
   PubMedGoogle Scholar
• Hechmati G, Cure S, Gouepo A, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ 2013;16:691-700
   PubMedGoogle Scholar
• Zometa, Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021223s034lbl.pdf
   Google Scholar
• Pamidronate, Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf
   Google Scholar
• Kim CHRK, Cheng PC, Smith J, eds. Bone targeting agent treatment patterns among patients with multiple myeloma treated at oncology clinics across the United States: observations from real-world data. San Diego, CA: American Society of Hematology; 2016
   Google Scholar
• Mahmood AGH, Fink MG, Patel M, et al. Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study. Community Oncol 2012;9:148-57
   Google Scholar